Safety and Innovation: Navigating the Challenges of Antibody-Drug Conjugates
This eBook provides scientists with more information on antibody–drug conjugates (ADCs), allowing you to further your research in this field.
What you will learn about:
- ADCs and monoclonal antibodies (mAbs)
- The manufacturing process
- Hazard assessments and protective measures
© Wiley
More Information
ADCs are a cutting-edge form of targeted cancer therapy that combines monoclonal antibodies with potent drugs. They target specific markers on cancer cells and deliver the drug directly to them. Advancements in antibody engineering and linkers are improving the design of these ADCs for increased efficacy and reduced side effects.
Articles contained in the collection:
- Pradhan, R. et al. (2022). Antibody–Drug Conjugates: Development and Applications, in Targeted Drug Delivery, Wiley, pp. 127–154.
- Ross, P.L. and Wolfe, J. (2016). Antibody–Drug Conjugates: An Overview of the CMC and Characterization Process, in Antibody‐Drug Conjugates, Wiley, pp. 59–83.
- Sussman, R. and Farris, J. (2016). Occupational Health and Safety Aspects of ADCs and Their Toxic Payloads, in Antibody‐Drug Conjugates, Wiley, pp. 151–175.
